公开(公告)号：CA3146307A1

公开(公告)日：2021-02-04

申请号：CA3146307

申请日：2020-07-29

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  NAKATSUGAWA MUNEHIDE ,  YAMASHITA YUKI ,  RAHMAN MUHAMMED AASHIQ ,  GUO TINGXI

IPC: C07K14/74

Abstract: The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DP beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 112 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 141 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.

公开(公告)号：AU2020319732A1

公开(公告)日：2022-03-03

申请号：AU2020319732

申请日：2020-07-29

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  SUGATA KENJI ,  GUO TINGXI

IPC: C07K14/74 ,  A61K38/17 ,  A61P31/00 ,  A61P35/00 ,  C12N15/12

Abstract: The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DR beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 114 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 143 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.

公开(公告)号：BR112022001702A2

公开(公告)日：2022-06-21

申请号：BR112022001702

申请日：2020-07-29

Applicant: UNIV HEALTH NETWORK

Inventor： SUGATA KENJI ,  HIRANO NAOTO ,  GUO TINGXI

IPC: A61K38/17 ,  A61P31/00 ,  A61P35/00 ,  C07K14/74 ,  C12N15/12

Abstract: moléculas mhc classe ii e métodos de uso das mesmas. a presente invenção refere-se a moléculas hla de classe ii possuindo uma afinidade maior para cd4 do que as moléculas hla de classe ii que ocorrem naturalmente. em certos aspectos, a molécula hla de classe ii compreende uma cadeia dr beta possuindo (i) um aminoácido que não leucina em uma posição correspondente ao resíduo de aminoácido 114 da seq id no: 1, (ii) um aminoácido que não a valina em uma posição correspondente ao resíduo de aminoácido 143 da seq id no: 1, (iii) ou ambos (i) e (ii). certos aspectos da presente invenção referem-se a moléculas de ácido nucleico que codificam as moléculas hla de classe ii, vetores compreendendo a molécula de ácido nucleico, células que compreendem as mesmas, e métodos de uso das mesmas.

公开(公告)号：AU2020323767A1

公开(公告)日：2022-03-03

申请号：AU2020323767

申请日：2020-07-29

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  NAKATSUGAWA MUNEHIDE ,  YAMASHITA YUKI ,  RAHMAN MUHAMMED AASHIQ ,  GUO TINGXI

IPC: C07K14/74 ,  A61P31/00 ,  A61P35/00 ,  C12N5/10 ,  C12N15/12 ,  C12Q1/02 ,  G01N33/566

Abstract: The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DP beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 112 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 141 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.

公开(公告)号：CA3146296A1

公开(公告)日：2021-02-04

申请号：CA3146296

申请日：2020-07-29

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  SUGATA KENJI ,  GUO TINGXI

IPC: C07K14/74

Abstract: The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DR beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 114 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 143 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.